Avstera Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Avstera Therapeutics is a private, clinical-stage biotech founded in 2018, focusing on oral small molecule therapies targeting RNA-binding proteins and HDAC6 for immuno-oncology and other diseases. Its lead asset, AVS100, is an IND-cleared, highly selective oral HDAC6 inhibitor for solid tumors, with a preclinical pipeline extending into cardiometabolic indications. The company is led by founder-CEO Karthik Musunuri and co-founder Ajay Raju, leveraging a foundation in immunology and strategic residency at J&J JLABS to advance its programs.

OncologyCardiometabolicCardiovascular

Technology Platform

Platform for developing highly selective, orally bioavailable small molecule inhibitors, primarily focused on HDAC6, to modulate immune cell function in the tumor microenvironment and inflammatory diseases.

Opportunities

The significant unmet need in immuno-oncology for patients unresponsive to checkpoint inhibitors presents a large market for AVS100 as a combination therapy.

Expanding the validated HDAC6 platform into the vast cardiometabolic disease space with oral therapies offers a substantial second wave of value creation.

Risk Factors

Primary risks include clinical failure of AVS100 to demonstrate safety or efficacy in human trials, and intense competition in the HDAC6 inhibitor space from other biopharma companies.

The company also faces financial risk as a pre-revenue entity dependent on raising capital to fund costly clinical development.

Competitive Landscape

Avstera competes in the selective HDAC6 inhibitor space for oncology with other biotechs and pharma companies. It also faces broader competition from numerous modalities (biologics, other small molecules) aiming to modulate the tumor microenvironment or treat cardiometabolic inflammation. Differentiation hinges on its compound's selectivity profile and clinical data.

More companies in Cell & Gene Therapy →More companies in United States →